Clinical trial
A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AGN-241751 After Oral Administration in Healthy Volunteers
NCT04981561 is registered in ClinicalTrials.gov with Syndeio Biosciences, Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AGN-241751 After Oral Administration in Healthy Volunteers
- Lead sponsor
- Syndeio Biosciences, Inc
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- December 9, 2016
- Completion date
- December 21, 2017
- Enrollment
- 68 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.